Hobbs, Brian D http://orcid.org/0000-0001-9564-0745
,
de Jong, Kim
Lamontagne, Maxime
Bossé, Yohan http://orcid.org/0000-0002-3067-3711
Shrine, Nick
Artigas, María Soler
Wain, Louise V http://orcid.org/0000-0003-4951-1867
Hall, Ian P
Jackson, Victoria E
Wyss, Annah B
London, Stephanie J http://orcid.org/0000-0003-4911-5290
North, Kari E
Franceschini, Nora
Strachan, David P http://orcid.org/0000-0001-7854-1366
Beaty, Terri H
Hokanson, John E
Crapo, James D
Castaldi, Peter J
Chase, Robert P
Bartz, Traci M
Heckbert, Susan R
Psaty, Bruce M
Gharib, Sina A
Zanen, Pieter
Lammers, Jan W
Oudkerk, Matthijs
Groen, H J
Locantore, Nicholas
Tal-Singer, Ruth
Rennard, Stephen I
Vestbo, Jørgen
Timens, Wim http://orcid.org/0000-0002-4146-6363
Paré, Peter D
Latourelle, Jeanne C
Dupuis, Josée
O'Connor, George T
Wilk, Jemma B
Kim, Woo Jin
Lee, Mi Kyeong
Oh, Yeon-Mok
Vonk, Judith M
de Koning, Harry J
Leng, Shuguang
Belinsky, Steven A
Tesfaigzi, Yohannes
Manichaikul, Ani
Wang, Xin-Qun
Rich, Stephen S
Barr, R Graham
Sparrow, David
Litonjua, Augusto A
Bakke, Per
Gulsvik, Amund
Lahousse, Lies http://orcid.org/0000-0002-3494-4363
Brusselle, Guy G
Stricker, Bruno H
Uitterlinden, André G
Ampleford, Elizabeth J
Bleecker, Eugene R
Woodruff, Prescott G
Meyers, Deborah A
Qiao, Dandi
Lomas, David A
Yim, Jae-Joon
Kim, Deog Kyeom
Hawrylkiewicz, Iwona
Sliwinski, Pawel
Hardin, Megan
Fingerlin, Tasha E
Schwartz, David A
Postma, Dirkje S
MacNee, William
Tobin, Martin D http://orcid.org/0000-0002-3596-7874
Silverman, Edwin K
Boezen, H Marike
Cho, Michael H http://orcid.org/0000-0002-4907-1657
,
,
,
,
,
,
Article History
Received: 6 July 2016
Accepted: 23 November 2016
First Online: 6 February 2017
Competing interests
: I.P.H. has received grant support from Pfizer. P.J.C. has received research funding from GlaxoSmithKline. B.P. serves on the data and safety monitoring board (DSMB) of a clinical trial funded by the manufacturer and on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. N.L. and R.T.-S. are shareholders and employees of GlaxoSmithKline. S.I.R. is a current employee and shareholder at AstraZeneca. He has served as a consultant, participated on advisory boards, and received honoraria for speaking or grant support from the American Board of Internal Medicine, Advantage Healthcare, Almirall, the American Thoracic Society, AstraZeneca, Baxter, Boehringer Ingelheim, Chiesi, ClearView Healthcare, the Cleveland Clinic, Complete Medical Group, CSL, Dailchi Sankyo, Decision Resources, Forest, Gerson Lehman, Grifols, GroupH, Guidepoint Global, Haymarket, Huron Consulting, Inthought, Johnson & Johnson, Methodist Health System–Dallas, NCI Consulting, Novartis, Pearl, Penn Technology, Pfizer, PlanningShop, PSL FirstWord, Qwessential, Takeda, Theron, and WebMD. W.T. reports fees to the Department, all outside the submitted work, from Pfizer, GSK, Chiesi, Roche Diagnostics/Ventana, Biotest, Merck Sharp Dohme, Novartis, Lilly Oncology, Boehringer Ingelheim, and grants from Dutch Asthma Fund. J.C.L. is currently an employee of GNS Healthcare. J.B.W. was employed by Pfizer during the time this research was performed. P.B. has received consulting and lecture fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, and Teva. L.L. has performed consultancy for Boehringer Ingelheim and has received an AstraZeneca Scientific Award and travel support from Novartis, the European Respiratory Society, and the Belgian Respiratory Society. P.G.W. has consulted for Amgen, Sanofi, Novartis, Genentech/Roche, Boehringer Ingelheim, and Neostem and has had research grants from Pfizer and Genentech. D.L. received grant support, honoraria, and consultancy fees from GlaxoSmithKline for work on the ICGN and ECLIPSE studies and was a member of and chaired the GSK Respiratory Therapy Area Board (2009–2015). M.H. is a current employee of AstraZeneca. D.A.S. is serving on the scientific advisory boards of Apellis Pharmaceuticals and Pliant Therapeutics, and is the founder and owner of Eleven P15. The University of Groningen has received money for D.S.P. with regard to a grant for research from AstraZeneca, Chiesi, Genentec, GlaxoSmithKline, and Roche. Fees for consultancies were given to the University of Groningen by AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Takeda, and TEVA. E.K.S. has received honoraria and consulting fees from Merck, grant support and consulting fees from GlaxoSmithKline, and honoraria and travel support from Novartis. M.H.C. has received grant support from GlaxoSmithKline.